PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 14 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

31 March 2026

  1. (diff | hist) 14:35 Talk:Purity claim inflation 748 +128 GradientGus (talk | contribs) /* Wavelength point */ reply
  2. (diff | hist) 13:25 Talk:Cost per milligram 611 +74 NPOV_Nadia (talk | contribs) /* The comparison cannot be made */ reply
  3. (diff | hist) 11:48 Dose escalation schedule 4,993 ±0 HOMA_Hettie (talk | contribs) space between number and unit per PP:MOS [rollback]
  4. (diff | hist) 11:10 Talk:Purity claim inflation 537 +171 Chromatokid (talk | contribs) /* Wavelength point */ new section
  5. (diff | hist) m b 10:12 Baseline laboratory panel 4,429 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]
  6. (diff | hist) 09:50 Talk:Cost per milligram 400 +144 CostPerMgCory (talk | contribs) /* The comparison cannot be made */ new section
  7. (diff | hist) 09:44 Talk:Multi-dose vial 1,233 +253 NPOV_Nadia (talk | contribs) /* Weight of the outbreak section */ reply
  8. (diff | hist) 09:15 Talk:Semaglutide 959 +208 DisclosureDido (talk | contribs) /* How much detail on research-chemical material? */ reply
  9. (diff | hist) 04:41 Subcutaneous injection 5,293 ±0 TirzTaxonomist (talk | contribs) add category for preparation and handling [rollback]

30 March 2026

  1. (diff | hist) 22:18 Temperature excursion 24,964 +325 ColdChainCleo (talk | contribs) correct the humidity figure — relative humidity needs its temperature [rollback]
  2. (diff | hist) m b 20:36 Nantong Guangyuan Chemical 15,114 ±0 StubSorterBot (talk | contribs) bot: sort category members [rollback]
  3. (diff | hist) 19:08 Peptide 6,813 ±0 CDMO_Caradoc (talk | contribs) clarify that "cold chain" without a logger is a claim, not a record [rollback]
  4. (diff | hist) 16:22 Talk:Multi-dose vial 1,022 +314 EndotoxinEd (talk | contribs) /* Weight of the outbreak section */ reply
  5. (diff | hist) 15:52 Body composition assessment 5,029 ±0 CPeptidePaddy (talk | contribs) add the interference the assay is known to be subject to [rollback]
  6. (diff | hist) m 15:44 Proglucagon 6,709 ±0 HalfLifeHavel (talk | contribs) typo [rollback]
  7. (diff | hist) 15:18 GenScript Peptides 17,613 ±0 LotTraceLuka (talk | contribs) add the minimum order quantity for custom synthesis [rollback]
  8. (diff | hist) 14:50 Talk:Semaglutide 748 +262 COA_Colwyn (talk | contribs) /* How much detail on research-chemical material? */ reply
  9. (diff | hist) 13:15 Talk:Grey market 611 +140 ScopeSeverin (talk | contribs) /* Is the term useful here at all? */ reply
  10. (diff | hist) 13:07 Talk:Multi-dose vial 811 +316 BalanceBirdie (talk | contribs) /* Weight of the outbreak section */ new section
  11. (diff | hist) 12:52 Good manufacturing practice 5,123 ±0 HedgeHedda (talk | contribs) state that a GMP claim is not a fact until assessed [rollback]
  12. (diff | hist) 10:22 Talk:Semaglutide 537 +180 ScopeSeverin (talk | contribs) /* How much detail on research-chemical material? */ new section
  13. (diff | hist) 09:40 Talk:Grey market 400 +184 GreyMarketGreer (talk | contribs) /* Is the term useful here at all? */ new section
  14. (diff | hist) 09:21 Injection site rotation 4,872 ±0 eGFR_Esme (talk | contribs) rm the individualised advice — the article describes, it does not instruct [rollback]
  15. (diff | hist) m 06:21 Albumin binding half-life extension 6,399 ±0 GIP_Genoveva (talk | contribs) expand §Design variables [rollback]
  16. (diff | hist) m 04:51 Lixisenatide 4,195 ±0 A1c_Alder (talk | contribs) the storage condition applies to the unopened pen; say so [rollback]
  17. (diff | hist) 03:38 Third-party testing 7,489 ±0 PrimarySrcPatia (talk | contribs) add the retest interval and what triggers one [rollback]
  18. (diff | hist) 02:54 Fmoc chemistry 4,618 ±0 SemaglutideSasha (talk | contribs) correct the eutectic temperature — source gives a range [rollback]
  19. (diff | hist) 01:32 Peptide harm reduction 4,800 ±0 PatientPanelPru (talk | contribs) add the manufacturer assistance programme with its eligibility criterion [rollback]

29 March 2026

  1. (diff | hist) m 16:45 Wuhan Wansheng Biotechnology 15,849 ±0 BlindSampleBrid (talk | contribs) add the storage and handling guidance the organisation publishes [rollback]
  2. (diff | hist) 14:39 Sangon Biotech 14,764 ±0 LedgerLysander (talk | contribs) consistent en dashes in ranges [rollback]
  3. (diff | hist) 12:09 Timeline of incretin therapeutics 4,460 ±0 AnalyticalAnnie (talk | contribs) typo [rollback]
  4. (diff | hist) 08:52 Sarcopenia 4,491 ±0 CPeptidePaddy (talk | contribs) serial comma per PP:MOS [rollback]
  5. (diff | hist) 04:17 Medutest 5,018 ±0 SecondarySrc_Seb (talk | contribs) add the difference between a batch certificate and a lot-specific one [rollback]

28 March 2026

  1. (diff | hist) 20:58 Dulaglutide 5,490 ±0 LiraLotte (talk | contribs) split overlong sentence [rollback]
  2. (diff | hist) 16:30 Amylin receptor agonist 5,245 ±0 TitrationTheo (talk | contribs) state which salt form the mass in the infobox refers to [rollback]
  3. (diff | hist) 14:06 Drug master file 4,325 ±0 ShortDescShai (talk | contribs) add the date the shortage listing ended [rollback]
  4. (diff | hist) 12:26 Resin cleavage 4,310 ±0 SPPS_Sorrel (talk | contribs) add the note that lyophilised material tolerates excursions better than solution [rollback]
  5. (diff | hist) 09:15 Talk:Reconstitution of lyophilised peptides 959 +81 NPOV_Nadia (talk | contribs) /* Register: description or instruction? */ reply
  6. (diff | hist) 07:29 Shenzhen Hybio Pharmaceutical 17,496 ±0 ToleranceTove (talk | contribs) add the research-use-only statement to the lead rather than only the footer [rollback]
  7. (diff | hist) 07:03 Shanghai Wibson Biotechnology 15,440 ±0 SecondarySrc_Seb (talk | contribs) add the outbound storefront link, marked nofollow and sponsored per the external-links convention [rollback]
  8. (diff | hist) 04:10 Shanghai ERP Biotechnology 14,637 +220 BlankVialBo (talk | contribs) convert the product range to a table so the documentation column lines up [rollback]

27 March 2026

  1. (diff | hist) 19:55 Customs seizure 4,785 ±0 PioneerPerdita (talk | contribs) convert the jurisdiction comparison to a table [rollback]
  2. (diff | hist) 14:55 Talk:CagriSema 748 +64 MolarMassMaeve (talk | contribs) /* Why not a unimolecular design? */ reply
  3. (diff | hist) 14:20 Talk:Reconstitution of lyophilised peptides 748 +172 StabilityStig (talk | contribs) /* Register: description or instruction? */ reply
  4. (diff | hist) 13:20 Talk:Sarcopenia 611 +101 LeanMassLars (talk | contribs) /* Strength first, mass second */ reply
  5. (diff | hist) m 11:56 Liraglutide 5,967 ±0 FigureFerdinand (talk | contribs) correct the molar mass — source gives the free-base figure, we had the salt [rollback]
  6. (diff | hist) 11:20 Talk:CagriSema 537 +217 ReceptorRhoda (talk | contribs) /* Why not a unimolecular design? */ new section
  7. (diff | hist) 10:40 Talk:Reconstitution of lyophilised peptides 537 +210 NPOV_Nadia (talk | contribs) /* Register: description or instruction? */ new section
  8. (diff | hist) 09:45 Talk:Sarcopenia 400 +124 SarcopeniaSefa (talk | contribs) /* Strength first, mass second */ new section
  9. (diff | hist) m 03:39 Grey market 4,279 ±0 B12_Bettina (talk | contribs) expand §What the term does not mean [rollback]

26 March 2026

  1. (diff | hist) 18:04 Satiety signalling 5,593 ±0 EmptyingElke (talk | contribs) expand §Central integration [rollback]
  2. (diff | hist) 15:26 Enteroendocrine L cell 5,083 ±0 LeaderLoic (talk | contribs) move a stray full stop inside the reference [rollback]
  3. (diff | hist) 13:15 Talk:Incretin effect 748 +258 AnalyticalAnnie (talk | contribs) /* Asymmetric loss in T2D — is the GIP figure sourced? */ reply
  4. (diff | hist) 10:48 Talk:Incretin effect 537 +330 CitationChaser (talk | contribs) /* Asymmetric loss in T2D — is the GIP figure sourced? */ new section
  5. (diff | hist) m 00:02 Lot traceability 5,317 ±0 BlindSampleBrid (talk | contribs) convert the service comparison to a table [rollback]

25 March 2026

  1. (diff | hist) 23:54 AmbioPharm 15,850 ±0 ForgeryFinder (talk | contribs) add the lead time for catalogue lines, as reported [rollback]
  2. (diff | hist) 14:00 Talk:Reference standard 748 +161 Chromatokid (talk | contribs) /* Circular calibration */ reply
  3. (diff | hist) 13:38 Vial 26,012 ±0 SPPS_Sorrel (talk | contribs) consistent en dashes in ranges [rollback]
  4. (diff | hist) 13:30 Talk:TRIUMPH trial programme 611 +187 PreregPriya (talk | contribs) /* Quoting phase 2 figures */ reply
  5. (diff | hist) 12:11 Hunan Aslsen Technology 15,492 ±0 HypoHildur (talk | contribs) add the storage and handling guidance the organisation publishes [rollback]
  6. (diff | hist) 10:30 Talk:Reference standard 537 +202 PrimarySrcPatia (talk | contribs) /* Circular calibration */ new section
  7. (diff | hist) 09:55 Talk:TRIUMPH trial programme 400 +132 TriumphThad (talk | contribs) /* Quoting phase 2 figures */ new section
  8. (diff | hist) m 06:50 CagriSema 5,687 ±0 NavboxNiko (talk | contribs) add the receptor targets to the lead sentence [rollback]

24 March 2026

  1. (diff | hist) 22:07 Hubei Jianxiang Bioscience 14,855 ±0 MOTSc_Mira (talk | contribs) expand §External links [rollback]
  2. (diff | hist) 18:44 Chinese Peptide Company 15,513 ±0 ArcuateArt (talk | contribs) expand §Corporate identity and history [rollback]
  3. (diff | hist) 16:39 Certificate of analysis 10,014 ±0 AnalyticalAnnie (talk | contribs) add the note that self-submitted reports are a self-selected sample [rollback]
  4. (diff | hist) 16:22 SinoPep 18,140 ±0 MTC_Marisol (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]
  5. (diff | hist) 15:33 Purity claim inflation 5,660 ±0 ForgeryFinder (talk | contribs) add the turnaround time the service publishes [rollback]
  6. (diff | hist) 15:16 Dual incretin agonist 5,851 ±0 ManualOfStyleMo (talk | contribs) give the strength per pen as well as per millilitre [rollback]
  7. (diff | hist) 14:20 Talk:Third-party testing 748 +126 Chromatokid (talk | contribs) /* Agreement between report and certificate */ reply
  8. (diff | hist) 13:25 Talk:Vial filling and stoppering 611 +115 BlankVialBo (talk | contribs) /* Vacuum check */ reply
  9. (diff | hist) 12:49 GLP-1 receptor 7,570 ±0 TechnicianTeal (talk | contribs) state that the receptor is a class B G-protein-coupled receptor [rollback]
  10. (diff | hist) 10:50 Talk:Third-party testing 537 +108 PrimarySrcPatia (talk | contribs) /* Agreement between report and certificate */ new section
  11. (diff | hist) 10:48 Peptide synthesis 5,649 ±0 RepackRadek (talk | contribs) add the excursion tolerance with the study it derives from [rollback]
  12. (diff | hist) 09:50 Talk:Vial filling and stoppering 400 +140 StopperingSteff (talk | contribs) /* Vacuum check */ new section
  13. (diff | hist) m 07:39 Reconstitution of lyophilised peptides 5,761 ±0 ChromCleanupCass (talk | contribs) rm the titration schedule — that belongs on the compound article [rollback]
  14. (diff | hist) 02:34 PolyPeptide Group (Hangzhou) 18,363 +495 TirzTaxonomist (talk | contribs) expand §Independent testing record [rollback]

23 March 2026

  1. (diff | hist) 23:19 Counterfeit peptide 5,488 ±0 VerifyFirstVida (talk | contribs) state the date range the submitted set covers [rollback]
  2. (diff | hist) m b 18:49 USP General Chapter 71 4,657 ±0 ArchiveBot (talk | contribs) bot: normalise unit spacing [rollback]
  3. (diff | hist) m 18:45 Intention-to-treat analysis 4,963 ±0 ReportReaderRilla (talk | contribs) the percentage quoted was placebo-adjusted; label it [rollback]
  4. (diff | hist) 15:46 ChinaPeptides 14,979 ±0 Chromatokid (talk | contribs) add the reception tally with its period and count stated [rollback]
  5. (diff | hist) 13:20 Talk:International nonproprietary name 611 +116 GlossaryGleb (talk | contribs) /* Stem table */ reply
  6. (diff | hist) 12:08 Reference standard 5,217 ±0 NAION_Noel (talk | contribs) add the system-suitability criteria the method actually specifies [rollback]
  7. (diff | hist) m 10:24 High-performance liquid chromatography 7,231 ±0 DiluentDiya (talk | contribs) add the forced-degradation conditions the claim rests on [rollback]
  8. (diff | hist) 09:45 Talk:International nonproprietary name 400 +153 INN_Ingrid (talk | contribs) /* Stem table */ new section
  9. (diff | hist) 09:20 Talk:GLP-1 receptor agonist 1,096 +103 ScopeSeverin (talk | contribs) /* Scope: how much research-chemical material belongs here? */ reply
  10. (diff | hist) m 05:43 Regulatory status by jurisdiction 4,444 ±0 PanelPlannerPam (talk | contribs) expand §Why status differs [rollback]
  11. (diff | hist) 04:37 Exenatide 5,754 ±0 OrforglipronOona (talk | contribs) add CAS number, sourced [rollback]

22 March 2026

  1. (diff | hist) 20:10 Vial filling and stoppering 4,833 ±0 SurrogateSunday (talk | contribs) rm the shipping recommendation — that is advice, not description [rollback]
  2. (diff | hist) 16:48 Talk:GLP-1 receptor agonist 885 +226 Peptide_Pete (talk | contribs) /* Scope: how much research-chemical material belongs here? */ reply
  3. (diff | hist) 14:05 Talk:GLP-1 receptor agonist 674 +173 ScopeSeverin (talk | contribs) /* Scope: how much research-chemical material belongs here? */ new section
  4. (diff | hist) 06:40 Trial data comparison 7,303 ±0 BPC_Bramwell (talk | contribs) add the axis labels to the inline bar figure [rollback]
  5. (diff | hist) 05:21 Limit of detection 4,865 ±0 Areapercent_Ayo (talk | contribs) fix hyphenation per PP:MOS [rollback]
  6. (diff | hist) m 04:39 Bacterial endotoxin test 5,317 ±0 PortalPolly (talk | contribs) correct the water-content figure — the source reports it on a dry basis [rollback]
  7. (diff | hist) 02:42 GenScript Peptides 17,613 +488 RegainRomilly (talk | contribs) correct the regional-warehouse list — six sites, not five [rollback]

21 March 2026

  1. (diff | hist) 20:55 Reverse-phase HPLC 5,499 ±0 VerifyFirstVida (talk | contribs) fix hyphenation per PP:MOS [rollback]
  2. (diff | hist) 17:25 Melanotan II 4,649 ±0 MOTSc_Mira (talk | contribs) label the secretagogue claim as receptor-level, not clinical [rollback]
  3. (diff | hist) 14:45 Talk:VendorInvestigate 748 +123 ReportReaderRilla (talk | contribs) /* Forgery limitation */ reply
  4. (diff | hist) 14:05 Weight regain after discontinuation 4,670 ±0 SupplyWatchSuri (talk | contribs) clarify that the effect resolved on discontinuation in the cited series [rollback]
  5. (diff | hist) 11:20 Talk:VendorInvestigate 537 +148 ForgeryFinder (talk | contribs) /* Forgery limitation */ new section